Core Viewpoint - Vivani Medical, Inc. has successfully closed a registered direct offering and a private placement, raising approximately $15.7 million to support its ongoing research and clinical development efforts [1][2]. Group 1: Offering Details - The company completed a registered direct offering of 6,000,000 shares and a private placement of 3,703,703 shares, both priced at $1.62 per share [1]. - The gross proceeds from these transactions are approximately $15.7 million, before deducting fees and offering expenses [1]. - ThinkEquity acted as the sole placement agent for the registered direct offering [2]. Group 2: Use of Proceeds - The net proceeds from the offerings will be utilized for ongoing research and clinical development of the company's product candidates, as well as for working capital and general corporate purposes [2]. Group 3: Company Overview - Vivani Medical, Inc. is a clinical-stage biopharmaceutical company that develops miniature, ultra long-acting drug implants using its proprietary NanoPortal™ platform [5]. - The company is focused on developing GLP-1 based implants aimed at treating metabolic diseases such as obesity and type 2 diabetes [5]. - The implants are designed to enhance patient adherence to medication by addressing challenges associated with daily or weekly administration of oral and injectable medications [5].

Core Viewpoint - Vivani Medical, Inc. has announced a registered direct offering and private placement of common stock, aiming to raise approximately $15.7 million to support ongoing research and clinical development of its product candidates [1][2]. Group 1: Offering Details - The company is offering 6,000,000 shares of common stock at $1.62 per share in a registered direct offering and an additional 3,703,703 shares in a concurrent private placement, also at $1.62 per share [1]. - The gross proceeds from both offerings are expected to be around $15.7 million before deducting fees and expenses [1]. - The offerings are set to close on or about October 28, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offerings will be utilized for ongoing research and clinical development of the company's product candidates, as well as for working capital and general corporate purposes [2]. Group 3: Company Overview - Vivani Medical, Inc. specializes in developing miniature, ultra long-acting drug implants using its proprietary NanoPortal™ platform, targeting metabolic diseases such as obesity and type 2 diabetes [5]. - The company's implants aim to improve patient adherence to medication by providing steady drug delivery over extended periods, addressing challenges associated with daily or weekly administration of oral and injectable medications [5]. - Approximately 50% of patients experience medication non-adherence, which Vivani aims to mitigate through its innovative drug delivery solutions [5].

Core Insights - Vivani Medical, Inc. is a clinical-stage biopharmaceutical company focused on developing miniature, ultra long-acting drug implants aimed at improving medication adherence and patient tolerance [1][4]. Group 1: Company Presentation - CEO Adam Mendelsohn, Ph.D., will present at the ThinkEquity Conference on October 30, 2025, at 1:30 p.m. Eastern Time in New York [1][2]. - The presentation will be available via webcast on Vivani's corporate website [2]. Group 2: Company Overview - Vivani utilizes its proprietary NanoPortal™ platform to create biopharmaceutical implants that deliver drug molecules steadily over extended periods [4]. - The company is developing a portfolio of GLP-1 based implants targeting metabolic diseases such as obesity and type 2 diabetes [4]. - Medication non-adherence affects approximately 50% of patients, including those on daily pills, highlighting the need for innovative delivery methods [4].

Core Viewpoint - Vivani Medical, Inc. is set to present at the Emerging Growth Conference 86 on September 25, 2025, showcasing its innovative drug delivery technology and engaging with investors [1][2]. Company Overview - Vivani Medical, Inc. is a clinical-stage biopharmaceutical company focused on developing miniature, ultra long-acting drug implants using its proprietary NanoPortal™ platform [6]. - The company aims to improve medication adherence and patient tolerance by providing steady drug delivery over extended periods, particularly targeting metabolic diseases such as obesity and type 2 diabetes [6]. Conference Details - The presentation will last for 30 minutes, starting at 1:45 pm Eastern Time, and will be accessible to both individual and institutional investors [3][5]. - Attendees are encouraged to submit questions in advance, and an archived webcast will be available post-conference [2][3]. Emerging Growth Conference - The conference serves as a platform for public companies to present their products and services to a broad audience of investors and analysts [4][5]. - It focuses on companies with strong management teams and innovative strategies, aiming to highlight their long-term growth potential [5].

Core Viewpoint - Vivani Medical, Inc. is preparing to present its innovative drug implant technology at the H.C. Wainwright 27th Annual Global Investment Conference, focusing on improving medication adherence and patient outcomes in chronic disease management [1][3]. Company Overview - Vivani Medical, Inc. is a clinical-stage biopharmaceutical company specializing in miniature, ultra long-acting drug implants [1][3]. - The company utilizes its proprietary NanoPortal™ technology to develop biopharmaceutical implants that deliver drug molecules steadily over extended periods [3]. - Medication non-adherence affects approximately 50% of patients, highlighting the need for innovative solutions [3]. Product Pipeline - The priority product candidate is NPM-139, a miniature, six-month, subdermal GLP-1 (semaglutide) implant aimed at chronic weight management in obese or overweight individuals [3]. - NPM-139 has the potential for once-yearly dosing, which could significantly enhance patient compliance [3]. - Other products in development include NPM-115 (exenatide implant) for chronic weight management and NPM-119 (exenatide implant) for type-2 diabetes treatment [3]. Upcoming Presentation Details - CEO Adam Mendelsohn will present on September 10, 2025, at the Lotte New York Palace Hotel, focusing on the company's innovative drug implant technology [1]. - The presentation is part of the H.C. Wainwright 27th Annual Global Investment Conference, which runs from September 8-10, 2025 [1].

Core Insights - Vivani Medical, Inc. has appointed Anthony Baldor as Chief Financial Officer, succeeding Brigid A. Makes, who is retiring to focus on other commitments [1][3] - Baldor has over 20 years of financial management experience in the biotechnology sector, with a strong background in fundraising and corporate strategy [2] - The CEO of Vivani, Adam Mendelsohn, expressed confidence in Baldor's expertise to advance the company's pipeline and operations during a critical period [3] Company Overview - Vivani Medical develops miniature, ultra long-acting drug implants using its proprietary NanoPortal™ platform, aimed at improving medication adherence and patient tolerance [4] - The lead program, NPM-115, is a six-month GLP-1 implant for chronic weight management, with additional products in the pipeline, including NPM-139 and NPM-119, targeting similar therapeutic areas [4] - Medication non-adherence affects approximately 50% of patients, contributing to over $500 billion in annual avoidable healthcare costs and 125,000 preventable deaths in the U.S. [4]